Co-Diagnostics, Inc. JV CoSara Diagnostics Recognized for Work Combating COVID-19 Surge in India

April 30, 2021

Co-Diagnostics’ Indian manufacturing facility, CoSara Diagnostics Pvt. Ltd. (“CoSara,” or the “JV”, a Joint Venture with Synbiotics Ltd) has been featured in recent press highlighting its actions to provide COVID-19 diagnostics as a surge of infections has led to the world’s worst COVID-19 outbreak since the pandemic began.

The article in the Times of India and others discusses the increased testing capacity that has resulted from CoSara’s efforts.

“CoSara forms an integral part of our mission to bring high-quality, affordable molecular diagnostics solutions to the world, especially to the people and countries who need them the most,” commented Dwight Egan, Company CEO.

“We’re proud of Co-Diagnostics’ dedication to bring COVID-19 diagnostics to India at this critical time,” said Kelvyn Cullimore, president and CEO of BioUtah. “From its first COVID test, the company has no left no stone unturned in bringing high-quality testing to our nation and the world.”

In particular, the press has noted the extraordinary efforts of a CoSara team of 6 women who have worked to increase capacity at the manufacturing facility from roughly 8,000 COVID-19 PCR tests per day a year ago to around 40,000 per day now, after being one of the first companies to provide PCR test kits to the state of Gujarat.

Mohal Sarabhai, CEO of Synbiotics, remarked, “In agreement with the ‘make in India‘ initiative and the response to the COVID-19 crisis, CoSara has risen to the occasion as we play a critical role in helping to stem the tide of infections spreading across the country.